ENTITY
HBM Holdings Limited

HBM Holdings Limited (2142 HK)

36
Analysis
Health CareHong Kong
HBM Holdings Limited operates as a biopharmaceutical company. The Company develops novel and highly differentiated antibody therapeutics in immunology and oncology disease areas. HBM Holdings provides its services throughout China.
more
Refresh
06 Dec 2020 11:36

ECM Weekly (6 December 2020) - Blue Moon Group, Pop Mart, HBM, Burger King India, and More

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
02 Dec 2020 09:36

Harbour Biomed IPO: Positive Thoughts in Brief

This Insight includes a brief analysis of Harbour Biomed and its proposed listing on the HKEX. We like the deal at the price range offered.

Share
01 Dec 2020 09:34

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

This article analyzed Harbour's core products, team, technology platforms, thoughts on valuation and the "hidden" value that is often easy to be...

Logo
314 Views
Share
30 Nov 2020 16:57

HBM Holdings (Harbour Biomed) IPO: Valuation Insights

Harbour has launched an HK IPO to raise net proceeds of $205 million at the mid-point of the price range. Overall, strong cornerstones and our...

Logo
687 Views
Share
30 Nov 2020 12:08

HBM (和铂医药) IPO: Strong Cornerstone Not a Performance Guarantee

HBM Holding IPO has attracted a strong line-up of cornerstone investors. But we think it is fairly valued at the high end.

Logo
263 Views
Share
x